

## Siemens Healthineers Integrates Hemostasis Product Offerings in United States and Europe

Siemens Healthineers and Sysmex Corporation have begun distributing independently their combined wide hemostasis testing [portfolio](#) to laboratories in the United States and Europe<sup>1</sup> under each company's respective own brands, offering healthcare providers streamlined access to leading hemostasis testing solutions that support several conditions and disease states patients face. Hemostasis testing is most often used to help identify and monitor bleeding and clotting disorders.

Newly integrated into the Siemens Healthineers portfolio are the CN-3000/6000,<sup>2</sup> CS-2500, CS-5100, and CA-600 series systems under the Siemens Healthineers brand. Supporting hemostasis testing needs for high-, mid-, and low-volume testing, the proven systems are designed to accelerate testing and streamline workflows, whether stand-alone or connected to lab automation.<sup>3</sup> Through integration with the Siemens Healthineers Atellica Diagnostics IT products, labs can centralize visibility and control over hemostasis testing processes to automatically manage repeat testing, integrate quality control processes, and improve key performance indicators such as turnaround time with built-in analytics. For lab networks with multiple locations and hemostasis analyzers, testing with hemostasis systems from Siemens Healthineers enables labs to produce standardized results across sites with excellent result correlation. These hemostasis testing systems join the broader in vitro diagnostics portfolio Siemens Healthineers provides, which includes chemistry, immunoassay, urinalysis, hematology, automation, and IT solutions.

"Today laboratories are confronted with a variety of operational and administrative tasks, and staff shortages require maximum productivity to be able to deliver test results for patients," said Robert Stowers, executive vice president and head of the Specialty Lab Solutions business for Diagnostics, Siemens Healthineers. "Through our collaborative agreement with Sysmex, both companies now offer a proven portfolio of hemostasis testing instruments and assays, which complement unique portfolio offerings that will greatly benefit laboratories worldwide."

Siemens Healthineers and Sysmex have built a solid partnership over 25 years, together becoming one of the leading solution providers in the global hemostasis segment. In February 2023, with the aim of providing broader and more effective hemostasis laboratory solutions to customers worldwide, the companies established an [agreement](#) to distribute their combined hemostasis portfolio, globally and

individually, under their respective company names, in combination with their own wider portfolios of products and services.

<sup>1</sup> Included EU member states, Iceland, Liechtenstein, and Norway.

<sup>2</sup> The products/features/applications mentioned here are not commercially available in all countries and are subject to local regulations. Their future availability cannot be guaranteed. Not available for sale in the U.S.

<sup>3</sup> Automation connectivity available for CN-3000/6000 Systems and CS-5100 System only.

CN-3000 and CN-6000 Systems refer to Automated Blood Coagulation Analyzer CN-3000 and Automated Blood Coagulation Analyzer CN-6000 respectively. CS-5100 System and CS-2500 System refer to Automated Blood Coagulation Analyzer CS-5100 and CS-2500 respectively.

CA-600 series Systems refer to CA-660 and CA-620 Systems. CA-660 and CA-620 Systems refer to Automated Blood Coagulation Analyzer CA-660 and Automated Blood Coagulation Analyzer CA-620 respectively.

###

## Media contact

Kimberly Nissen

+1 610-241-2129; [Kimberly.Nissen@siemens-healthineers.com](mailto:Kimberly.Nissen@siemens-healthineers.com)

Follow the press team [on X](#).

Visit the [Siemens Healthineers Press Center](#).

**Siemens Healthineers** pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2023, which ended on September 30, 2023, Siemens Healthineers had approximately 71,000 employees worldwide and generated revenue of around €21.7 billion. Further information is available at [www.siemens-healthineers.com](http://www.siemens-healthineers.com).